文献速递浆细胞疾病

miR-375的表观遗传沉默是多发性骨髓瘤中PDPK1/RPS6KA3信号轴组成性激活的主要机制

Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple myeloma.
PubMed 文献 · Br J Haematol · 2017-04-25

研究分析30例意义未明的单克隆丙种球蛋白病和73例多发性骨髓瘤患者浆细胞,发现miR-375表达较正常浆细胞显著降低且与临床分期无关。在骨髓瘤细胞系中,miR-375可下调PDPK1、IGF1R和JAK2;MIR375启动子CpG岛在全部8个细胞系和多数58例患者骨髓瘤细胞中呈病理性高甲基化。去甲基化药物SGI-110和/或组蛋白去乙酰化酶抑制剂曲古抑菌素A可恢复miR-375表达并抑制上述靶点。

要点

  • 多发性骨髓瘤患者浆细胞miR-375表达较正常浆细胞显著降低,且与临床分期无关。
  • miR-375可下调骨髓瘤细胞系中PDPK1、IGF1R和JAK2表达。
  • MIR375启动子CpG岛在全部8个细胞系和多数58例患者骨髓瘤细胞中高甲基化。

核心结论

  • 重叠的表观遗传失调普遍参与多发性骨髓瘤中miR-375的异常沉默,可能通过激活致癌信号通路促进骨髓瘤发生和进展。

研究设计与样本

  • 研究分析30例意义未明的单克隆丙种球蛋白病和73例多发性骨髓瘤患者来源的浆细胞,以及人骨髓瘤细胞系(HMCLs)。

主要发现

  • 与正常浆细胞相比,患者来源浆细胞miR-375表达显著降低,且与临床分期无关。
  • 在人骨髓瘤细胞系中导入miR-375可降低PDPK1表达,并下调IGF1R和JAK2。
  • MIR375启动子CpG岛在全部8个受检HMCLs和多数58例患者来源骨髓瘤细胞中呈病理性高甲基化。
  • SGI-110和/或曲古抑菌素A处理可增加HMCLs中miR-375表达,并抑制PDPK1、IGF1R和JAK2。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cytogenetic/molecular heterogeneity is the hallmark of multiple myeloma (MM). However, we recently showed that the serine/threonine kinase PDPK1 and its substrate RPS6KA3 (also termed RSK2) are universally active in MM, and play pivotal roles in myeloma pathophysiology. In this study, we assessed involvement of aberrant miR-375 repression in PDPK1 overexpression in MM. An analysis of plasma cells from 30 pre-malignant monoclonal gammopathies of undetermined significance and 73 MM patients showed a significant decrease in miR-375 expression in patient-derived plasma cells regardless of the clinical stage, compared to normal plasma cells. Introduction of miR-375 reduced PDPK1 expression in human myeloma cell lines (HMCLs), indicating that miR-375 is the dominant regulator of PDPK1 expression. In addition, miR-375 introduction also downregulated IGF1R and JAK2 in HMCLs. CpG islands in the MIR375 promoter were pathologically hypermethylated in all 8 HMCLs examined and in most of 58 patient-derived myeloma cells. Treatment with SGI-110, a hypomethylating agent, and/or trichostatin A, a histone deacetylase inhibitor, increased miR-375 expression, but repressed PDPK1, IGF1R and JAK2 in HMCLs. Collectively, these results show the universal involvement of overlapping epigenetic dysregulation for abnormal miR-375 repression in MM, which is likely to contribute to myelomagenesis and to subsequent myeloma progression by activating oncogenic signalling pathways.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Tatekawa S, Chinen Y, Ri M, et al. Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple myeloma. Br J Haematol. 2017. PMID: 28439875. doi:10.1111/bjh.14707

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。